Evidence map›Paper›PMID 32701251›Full record

ArticleAnti-cancer drugs2020

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.

Na Zhang, Pan Sun, Haizhen Jin, Yuqin Yang, Qingya Zhao, Lin Zhou, Lili Guo, Xiaohua Yang, Liming Lu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anti-cancer drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Discovery of novel polysubstitutedJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Na ZhangCentral Laboratory, Shanghai Chest Hospital, Shanghai JiaoTong University.
Pan SunCentral Laboratory, Shanghai Chest Hospital, Shanghai JiaoTong University.
Haizhen JinCentral Laboratory, Shanghai Chest Hospital, Shanghai JiaoTong University.
Yuqin YangLaboratory animal Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine.
Qingya ZhaoCentral Laboratory, Shanghai Chest Hospital, Shanghai JiaoTong University.
Lin ZhouCentral Laboratory, Shanghai Chest Hospital, Shanghai JiaoTong University.
Lili GuoCentral Laboratory, Shanghai Chest Hospital, Shanghai JiaoTong University.
Xiaohua YangCentral Laboratory, Shanghai Chest Hospital, Shanghai JiaoTong University.
Liming LuDepartment of Immunology, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shanghai Jiao Tong University · CNShanghai Chest Hospital · CNShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDAC inhibitors. In China, Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. However, the efficacy of Chidamide in non-small cell lung cancer remains unclear. In this study, we used lung cancer primary cells and investigated the effects of Chidamide combined with paclitaxel on lung cancer. We found that Chidamide combined with paclitaxel effectively inhibited the expression and activity of HDAC in primary lung cancer cells, induced their apoptosis and blocked cell cycle. Chidamide combined with paclitaxel may therefore provide a new promising therapeutic treatment for lung cancer.

Indexed as

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsApoptosisBenzamidesCarcinoma, Non-Small-Cell LungCell CycleHistone Deacetylase 3Histone Deacetylase 6Histone Deacetylase InhibitorsHistone DeacetylasesHumansLung NeoplasmsPaclitaxelProto-Oncogene Proteins c-mycTumor Cells, CulturedAminopyridinesBenzamidesHDAC6 protein, humanHistone Deacetylase 3Histone Deacetylase 6Histone Deacetylase InhibitorsHistone DeacetylasesMYC protein, humanN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamidePaclitaxelProto-Oncogene Proteins c-myc

Identifiers

PMID32701251
PMCPMC7365669
OpenAlexW3016894788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.